Author:
Heininger K.,Klimke A.,Gaebel W.,Bandelow B.,Rüther E.,Klieser E.,Lemmer W.
Reference36 articles.
1. Balant-Gorgia AE, Balant LP (1993) Psychotropic drug metabolism and clinical monitoring. In: Gram LF, Balant LP, Meltzer HY, Dahl SG (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 212–229
2. Bareggi SR, Mauri M, Cavallaro R, Regazzetti MG, Moro AR (1990) Factors affecting the clinical response to haloperidol therapy in schizophrenia. Clin Neuropharmacol 13 [Suppl]: S29–S34
3. Borgström L, Larsson H, Molander L (1982) Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol 23: 173–176
4. Breyer-Pfaff U (1987) Klinische Pharmakokinetik der Neuroleptika: Ergebnisse und Probleme. In: Pichot P, Möller H-J (Hrsg) Neuroleptika. Springer, Berlin Heidelberg New York Tokyo, S 37–46
5. Chang WH (1992) Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacology 106: 289–296